Clinical Data From Infinity's Hsp90 Chaperone Inhibitor Program to be Presented During ASCO Meeting


CAMBRIDGE, Mass., May 13, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting clinical data on its novel Hsp90 chaperone inhibitor, IPI-504, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Fla. from May 29 through June 2, 2009.

The presentations for Infinity's Hsp90 chaperone inhibitor program are as follows:


 Saturday, May 30, 2009:  8:00 a.m. - 12:00 p.m. EDT
 Poster Session Title: A phase 1b trial of IPI-504 (retaspimycin
 hydrochloride), a novel Hsp90 inhibitor, in combination with
 docetaxel
 Presenter: Gregory J. Riley, MD, PhD
 Location: Level 2, West Hall C, Poster Section G19

 Saturday, May 30, 2009:  2:00 - 6:00 p.m. EDT
 Poster Session Title: A phase II trial of IPI-504 (retaspimycin
 hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed
 and/or refractory state IIIb or stage IV non-small cell lung cancer
 (NSCLC) stratified by EGFR mutation status
 Presenter: Lecia V. Sequist, MD, MPH
 Location: Level 2, West Hall C, Poster Section P18

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.



            

Coordonnées